Cubebin

Synonyms: (-)-Cubebin
Cubebin((-)-Cubebin)是一种二苄基丁内酯木脂素,也是一种具有口服活性的 AChE 抑制剂,可通过氢键和疏水相互作用结合 NF-κB、TNF-α 和 TGF-β1 的活性位点并阻断关键残基,从而抑制促炎或肾纤维化相关活性,同时可增强 p38 MAPK 的磷酸化水平以上调酪氨酸酶基因表达,并通过提升酪氨酸酶的活性、表达量及 mRNA 水平刺激黑素生成,还可通过增强内源性抗氧化酶活性、抑制脂质过氧化来减轻氧化应激,调节脂质代谢、改善血糖控制,并通过降低肾功能损伤标志物水平、改善肾脏结构发挥肾脏保护作用;此外,Cubebin 具有抗菌活性,对广州管圆线虫幼虫具有杀幼虫活性,且对猴细胞系、人细胞系及秀丽隐杆线虫无细胞毒性,可用于糖尿病肾病、黑色素瘤、结肠腺癌、脑管圆线虫病、阿尔茨海默病 (AD) 及抑郁症的相关研究。
产品编号: MS-A44249 CAS No.: 18423-69-3 分子式: C20H20O6 分子量: 356.37
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价

产品描述

Cubebin((-)-Cubebin)是一种二苄基丁内酯木脂素,也是一种具有口服活性的 AChE 抑制剂,可通过氢键和疏水相互作用结合 NF-κB、TNF-α 和 TGF-β1 的活性位点并阻断关键残基,从而抑制促炎或肾纤维化相关活性,同时可增强 p38 MAPK 的磷酸化水平以上调酪氨酸酶基因表达,并通过提升酪氨酸酶的活性、表达量及 mRNA 水平刺激黑素生成,还可通过增强内源性抗氧化酶活性、抑制脂质过氧化来减轻氧化应激,调节脂质代谢、改善血糖控制,并通过降低肾功能损伤标志物水平、改善肾脏结构发挥肾脏保护作用;此外,Cubebin 具有抗菌活性,对广州管圆线虫幼虫具有杀幼虫活性,且对猴细胞系、人细胞系及秀丽隐杆线虫无细胞毒性,可用于糖尿病肾病、黑色素瘤、结肠腺癌、脑管圆线虫病、阿尔茨海默病 (AD) 及抑郁症的相关研究。

生物实验数据

生物活性 Cubebin ((-)-Cubebin), a dibenzylbutyrolactone lignan, is an orally active AChE inhibitor that binds the active sites of NF-κB, TNF-α, and TGF-β1 through hydrogen bonding and hydrophobic interactions and blocks key residues to inhibit pro-inflammatory or renal fibrosis-related activities; it enhances p38 MAPK phosphorylation to upregulate tyrosinase gene expression and stimulates melanogenesis by increasing tyrosinase activity, expression, and mRNA levels, alleviates oxidative stress by enhancing endogenous antioxidant enzyme activity and inhibiting lipid peroxidation, modulates lipid metabolism and improves glycemic control, and exerts renal protective effects by reducing the levels of markers of renal injury and improving renal structure; in addition, Cubebin exhibits antibacterial activity, larvicidal activity against Angiostrongylus cantonensis larvae, and no cytotoxicity toward monkey cell lines, human cell lines, or Caenorhabditis elegans, and can be used in research related to diabetic nephropathy, melanoma, colon adenocarcinoma, angiostrongyliasis, Alzheimer's disease (AD), and depression.
IC50 & Target

AChE

 

体外研究
(In Vitro)

Cubebin (2-20 μM; 72 h) 可在小鼠 B16 黑色素瘤细胞中以浓度依赖的方式刺激黑色素生成,在 2、5 和 10 μM 浓度下对细胞增殖无显著影响。
Cubebin (10 μM; 24-96 h) 可增强酪氨酸酶活性,并且在小鼠 B16 黑色素瘤细胞中,从 48 h 开始显著增加细胞内黑色素含量,在 72 h 和 96 h 时达到最高水平。
Cubebin (10 μM; 24-72 h) 可增强小鼠 B16 黑色素瘤细胞中酪氨酸酶蛋白的表达,在作用 48 h 时,其表达量相对于处理前细胞提升至 6.2 倍。
Cubebin (10 μM; 12-48 h) 可上调酪氨酸酶 (tyrosinase)的 mRNA 表达,在小鼠 B16 黑色素瘤细胞中,12 h 时其表达量相对于处理前细胞升高 1.8 倍。
Cubebin (10 μM; 2-12 h) 可在 4-8 h 时显著增强小鼠 B16 黑色素瘤细胞中 p38 MAPK 的磷酸化水平,而对 ERK1/2 或 p70 S6K1 的磷酸化无影响。
Cubebin (2.8-280 μM; 24-72 h) 对 HT29 细胞的作用表现为:在 2.8 μM 和 28 μM 浓度下处理 24、48 或 72 h 时无细胞毒性,但在 280 μM 浓度下处理 24、48 或 72 h 时会诱导显著的细胞毒性 (24 h 时细胞活力下降约 50%)。
Cubebin (50-200 μM; 24 h) 对 Vero 猴肾上皮细胞或 HaCaT 人角质形成细胞无细胞毒性,其作用浓度最高可达 200 μM,因此对广州管圆线虫幼虫具有较高的选择性指数。

Cell Proliferation Assay

Cell Line: murine B16 melanoma cells
Concentration: 2, 5, 10, 20 μM
Incubation Time: 72 h
Result: Stimulated melanogenesis in a concentration-dependent manner.
Significantly increased melanin amount at 2 μM relative to control cells.
Showed greater significant increases in melanin amount at 5, 10, and 20 μM relative to control cells.
Showed no significant effects on cell proliferation at 2, 5, and 10 μM.
Slightly decreased cell proliferation at 20 μM.

Western Blot Analysis

Cell Line: murine B16 melanoma cells
Concentration: 10 μM
Incubation Time: 24, 48, 72 h
Result: Enhanced tyrosinase expression to 4.9-fold of pre-treated cells at 24 h.
Enhanced tyrosinase expression to 6.2-fold of pre-treated cells at 48 h.
Enhanced tyrosinase expression to 1.7-fold of pre-treated cells at 72 h.

RT-PCR

Cell Line: murine B16 melanoma cells
Concentration: 10 μM
Incubation Time: 12, 24, 48 h
Result: Increased tyrosinase mRNA expression 1.8-fold relative to pre-treated cells at 12 h.
Showed 1.7-fold increases in tyrosinase mRNA expression at 24 and 48 h relative to pre-treated cells.

Western Blot Analysis

Cell Line: murine B16 melanoma cells
Concentration: 10 μM
Incubation Time: 2, 4, 6, 8, 10, 12 h
Result: Significantly enhanced phosphorylation of p38 MAPK at 4-8 h after treatment.
Showed no effects on the phosphorylation levels of ERK1/2 or p70 S6K1.

RT-PCR

Cell Line: murine B16 melanoma cells
Concentration: 10 μM
Incubation Time: 12 h
Result: Increased tyrosinase mRNA expression 1.9-fold relative to pre-treated cells.
Showed complete block of this cubebin-induced increase in tyrosinase mRNA expression when co-treated with SB203580.
体内研究
(In Vivo)

Cubebin (10-20 mg/kg;口服;每日一次;持续 8 周) 可显著改善 Streptozotocin (MS-Q80520) 诱导的糖尿病肾病大鼠的血糖控制、脂质代谢、肾功能、氧化应激水平、炎症标志物水平及肾脏组织病理学改变。
Cubebin (10 mg/kg;口服;单次给药) 可抑制角叉菜胶诱导的大鼠足肿胀达 53%,具有统计学意义的抗炎活性。
Cubebin (10 mg/kg;口服;单次给药) 可抑制 PGE2 诱导的大鼠足肿胀达 20%,具有统计学意义的抗炎活性。
Cubebin (10 mg/kg;口服;单次给药) 可抑制 5-羟色胺诱导的大鼠足肿胀,抑制率达 23%,具有统计学意义的抗炎活性。
Cubebin (10 mg/kg;口服;单次给药) 对角叉菜胶诱导的大鼠腹腔细胞迁移未产生统计学意义的抑制作用,仅观察到 12%的抑制率。
Cubebin (10 mg/kg;口服;单次给药) 可使醋酸诱导的小鼠扭体反应抑制率达 50%,具有统计学意义的外周镇痛活性。
Cubebin (10 mg/kg;口服;单次给药) 可抑制 PGI2 诱导的小鼠扭体反应达 71%,具有统计学意义的外周镇痛活性。
Cubebin (10-40 mg/kg;每日;连续 35 天) 可通过恢复脑内神经递质水平、减轻神经组织损伤及调控肠道菌群组成与功能,显著改善雄性 C57BL/6 小鼠由 CUMS 诱导的抑郁样行为。

Animal Model: Wistar (male, 8-10-week-old, 180 g, Streptozotocin-induced diabetic nephropathy)
Dosage: 10 mg/kg; 20 mg/kg
Administration: p.o.; daily; 8 weeks
Result: Significantly reduced fasting blood glucose levels and restored serum insulin levels.
Significantly reduced HbA1c levels.
Significantly reduced total cholesterol and triglyceride levels, and increased high-density lipoprotein levels.
Significantly reduced serum creatinine, blood urea nitrogen, and 24-hour urine volume.
Significantly increased kidney superoxide dismutase, catalase, and glutathione reductase activity, and reduced kidney malondialdehyde levels.
Significantly reduced kidney tumor necrosis factor-α, interleukin-1β, interleukin-6, nuclear factor-kappa B, and transforming growth factor-β1 levels.
Significantly improved renal histopathology, restoring normal glomerular and tubular structures and reducing lesions including glomerular basement membrane thickening, cellular necrosis, interstitial inflammation, and hemorrhage.
Animal Model: C57BL/6 (male, 6-8 weeks old, 18-22 g, CUMS-induced depression-like behavior)
Dosage: 10 mg/kg; 20 mg/kg; 40 mg/kg
Administration: i.g.; daily; 35 days
Result: Significantly increased total distance traveled in the open field test and sucrose preference percentage, and significantly decreased immobility time in the tail suspension test and forced swimming test compared to the model group.
Reduced pathological damage to hippocampal and cortical neuronal cells, with restored arrangement, number, and morphology of neurons compared to the model group; significantly increased cortical neuron count in the 40 mg/kg group compared to the model group.
Significantly increased norepinephrine (NE) and dopamine (DA) levels in cortical tissue in the 20 mg/kg and 40 mg/kg groups compared to the model group; significantly increased NE levels in hypothalamic tissue in all dose groups, and significantly increased DA levels in hypothalamic tissue in the 20 mg/kg group compared to the model group; significantly increased serotonin (5-HT) levels in cortical tissue in all dose groups compared to the model group.
Reversed CUMS-induced gut microbiota alterations, including reduced relative abundance of Clostridium, Dorea, Ruminococcus, Eubacterium, Escherichia, Phascolarctobacterium, Lactobacillus, Roseburia, Coprococcus, Sutterella, Akkermansia, Parabacteroides, and Allobaculum, and increased relative abundance of Prevotella, Dehalobacterium, Flavobacterium, and Blautia compared to the model group.
Reversed CUMS-induced dysregulation of gut microbiota metabolic pathways, with restored expression levels of KEGG and COG pathway sequences toward control group levels.

化学信息

分子量 356.37
分子式 C20H20O6
CAS No. 18423-69-3
别名 (-)-Cubebin

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础